SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant volatility following earnings results that beat top and bottom-line estimates but revealed deep-seated concerns regarding soft consumer demand in China and lackluster innovation. The community is sharply divided, with bulls pointing to the company's iconic brand status and potential for a long-term turnaround, while bears are aggressively shorting the stock, citing stagnant growth, a loss of market share to rising competitors, and skepticism toward management's long-term strategy.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors rotate into undervalued software companies, with many market participants viewing the stock as a critical 'orchestration layer' for safely monetizing and governing enterprise AI. The community is heavily focused on the high short interest and aggressive share buybacks, leading to ongoing speculation that these factors are priming the stock for a potential short squeeze.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing significant volatility as market participants weigh potential competitive pressure from new industry stablecoin consortia against long-term bullish expectations tied to the upcoming Clarity Act. While the community remains divided between those capitalizing on the dip as a long-term accumulation opportunity and those frustrated by recent technical weakness and insider selling, the stock continues to be heavily influenced by its status as a high-beta proxy for broader crypto-market sentiment and regulatory developments.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella is seeing significant investor interest driven by a pivot toward physical AI and robotics, with the stock catching momentum as institutional positioning increases. The community is actively discussing its role as a specialized hardware enabler for real-world AI perception and edge computing, balancing optimism over these growth cycles against concerns regarding the competitive semiconductor landscape.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is seeing intense community debate as investors weigh strong brand loyalty and international growth prospects against concerns over recent stock performance, management communication, and increased sector competition. While many investors are positioning for a potential recovery driven by strategic distribution partnerships, world-class growth trends, and heavy short interest, others remain cautious due to volatile price action and broader sector rotation risks.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending due to significant retail interest in a potential short squeeze, fueled by its inclusion in the Russell Microcap Value Index and active discussions regarding its low float and high short interest compared to sector peers like Wendy's. Investors are actively debating the company's turnaround potential, debt refinancing plans, and the aggressive bullish sentiment surrounding its ability to surge as short sellers are pressured.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The software sector is currently experiencing a strong rotation as investors pivot from overextended semiconductor and hardware momentum trades into software stocks. Community discussion centers on this trend as a potential bottoming process, with traders highlighting the resilience of established enterprise software names and their role in future AI agent monetization.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is currently generating significant market attention due to its expanding partnership with Jazz Pharmaceuticals to develop next-generation T-cell engager therapies, a move seen by the community as a major validation of its drug discovery platform. Investors are closely monitoring upcoming clinical trial readouts, viewing the company's proprietary technology and robust cash position as key indicators of its long-term potential in the AI-driven biotech sector.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors aggressively rotate into semiconductor leaders amid a record-breaking rally, fueled by a combination of new analyst price target hikes and sustained momentum in the AI infrastructure buildout. The community remains heavily focused on the stock's ability to maintain its technical breakout, with bullish sentiment tracking towards upcoming supply chain catalysts while bears continue to flag valuation concerns.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility and aggressive short-selling, with investors debating whether the stock is a deep-value opportunity for long-term growth or a failing play amid broader consumer sector weakness. The community is actively discussing the company's brand expansion, potential tariff catalysts, and the likelihood of a rebound following recent sharp pullbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corp Appoints Andrew Gengos As CFO

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16...

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

Equity

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.


Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...

Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMRXImmuneering Corp

Latest IMRX News